OTC Markets EXMKT - Delayed Quote USD

HTG Molecular Diagnostics, Inc. (HTGMQ)

0.0001
0.0000
(0.00%)
At close: April 23 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. John L. Lubniewski President, CEO & Director 821.19k -- 1964
Mr. Shaun D. McMeans Senior VP, CFO, Secretary & Treasurer 533.97k -- 1962
Ms. Laura Lee Godlewski Senior Vice President of Finance & Administration -- -- 1980
Dr. Debra A. Gordon J.D., Ph.D. Senior VP & Chief Legal Counsel 219.47k -- 1960
Dr. Patrick C. Roche Senior Vice President of Research & Development 257.58k -- 1953
Dr. Stephen A. Barat Ph.D. Senior Vice President of Therapeutics -- -- 1970
Dr. Christina M. Carruthers Ph.D. Vice President of Target Strategy & Early Development -- -- --
Debrah Thompson Vice President of Scientific Innovation -- -- --

HTG Molecular Diagnostics, Inc.

3430 East Global Loop
Tucson, AZ 85706
United States
877 289 2615 https://www.htgmolecular.com
Sector: 
Healthcare
Full Time Employees: 
53

Description

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Corporate Governance

HTG Molecular Diagnostics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

November 23, 2020 at 12:00 AM UTC

Dividend Date